Print Page Print Page
E-mail Page E-mail Page
RSS Feeds RSS Feeds
X
Share Page Share Page
E-mail Alerts E-mail Alerts
Financial Tear Sheet Financial Tear Sheet

Investor Relations

Overview
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, and commercial launch commenced in March 2016. OTO-104 is a steroid in development for the treatment of Ménière's disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are underway, with results expected during the second half of 2017. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that is in a Phase 1 clinical safety trial. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.
Stock Quote
OTIC (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$18.15
Change (%) Stock is Up 0.75 (4.31%)
Volume213,613
Data as of 12/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: OTIC.OQ.  Currently trading at $18.15 with a 52 week high of $30.75 and a 52 week low of $10.50.
Recent NewsMore >>
DateTitle 
11/30/16Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific OfficerPrinter Friendly Version
11/22/16Otonomy to Present at Piper Jaffray Healthcare ConferencePrinter Friendly Version
Investor Presentations
Download Documentation Corporate Presentation – November 30, 2016
Download Documentation Investor and Analyst Day Presentation – October 7, 2016
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources